SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reports of Jensen Huangs possible removaland widespread, unconfirmed claims that he has stepped downare driving concern about NVIDIAs leadership and the companys dependence on its founder. Traders are divided between fearing a prolonged hit to confidence and viewing the selloff as overdone because the underlying business remains intact.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius shares are drawing attention after a strong quarterly revenue beat was overshadowed by managements outlook for revenue near the low end of its 2026 range, delayed capacity and revenue milestones, and sharply higher planned capital spending. Traders are divided: bulls point to strong AI demand and customer prepayments to fund much of the buildout, while bears worry about execution delays, financing needs, and potential dilution; broader uncertainty around Nvidia is also weighing on sentiment.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondass Q3 results and higher forward outlook are driving attention, with traders highlighting strong revenue growth, bookings and backlog alongside an accelerated profitability timeline. Optimism about execution and a possible short squeeze is tempered by concerns over weaker margins, cash burn and the stocks volatile reaction.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines quarterly results are driving attention, with traders cheering a revenue and cash-flow beat, record backlog, and upbeat full-year outlook. Bulls see evidence of improving execution, while skeptics point to continuing operating losses, one-time items, and the need to convert backlog into sustained billings and profits.

Figure Technology Solutions, Inc. is a blockchain-native capital marketplace, which engages in connecting origination, funding, and secondary market activity. It operates through the following segments: FTI, Markets, and Other. The FTI segment offers Figure Connect which generates ecosystem and technology fees, and originates, sells, and securitizes home equity line of credit (HELOC) loans that it services. The Markets segment utilizes blockchain technology to develop an exchange for digital assets and credit, with new product offerings including providing interest-bearing stable coin deposits. The company was founded by Michael Scott Cagney and June Ou in 2018 and is headquartered in Reno, NV.

Figure Technology Solutions Inc. - Ordinary Shares - Class A

Figure Technology Solutions Inc

Figures Q3 earnings and revenue beat, alongside an expanded share-buyback authorization, are driving attention. Bulls point to growth and improving operating leverage, while bears focus on take-rate and guidance concerns, persistent selling, and alleged short pressure.

Boost Run, Inc. is a provider of scalable cloud infrastructure purpose-built for enterprise AI and high-performance computing workloads. The platform delivers GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. The company was founded on September 5, 2025 and is headquartered in Northbrook, IL.

Boost Run Inc. - Ordinary Shares - Class A

Boost Run Inc.

BRUN is drawing attention after its Q3 results showed sharp year-over-year revenue growth but fell short of expectations. Traders are split: bulls point to the multibillion-dollar contract backlog and project financing, while skeptics question whether the company can convert that backlog into sustained revenue and profitability.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Hot inflation data and rising Treasury yields and the dollar have pressured gold as traders price in a more hawkish Fed outlook. The community is split between expecting further declines and buying the dip, with some arguing that inflation, debt concerns and golds safe-haven role support a rebound.

Cardinal Infrastructure Group, Inc. provides infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. It delivers wet utility installations of water, sewer, and stormwater systems, as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. The company was founded on June 12, 2025 and is headquartered in Raleigh, NC.

Cardinal Infrastructure Group Inc - Ordinary Shares - Class A

Cardinals Q3 results and withdrawal of its 2026 outlookamid a sharp margin squeeze tied to project estimate revisionsare driving the discussion. Many traders fault management and fear further downside, while others view the selloff as excessive and point to the buyback authorization, preserved cash, and postponed Hughes deal as potential positives.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Trading is focused on the approaching FDA decision on Capricors Deramiocel application for Duchenne muscular dystrophy, particularly the revised upper-limb-function indication. Many traders are optimistic and speculate that short covering could amplify the rally, while others stress that the outcome remains uncertain given the earlier advisory committee concerns.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Reports of Nvidia weighing a leadership change have fueled a rotation into AMD, with traders betting customers may diversify toward rival AI-chip suppliers. The community is divided over whether the move signals a lasting opportunity for AMD or a short-lived sympathy rally, since Nvidias competitive edge and AMDs ability to win business remain debated.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes Precigen (PGEN) a New Buy Stock

Precigen (PGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PGEN Q3 Earnings Call Highlights Launch Momentum and Competition

Precigen's PAPZIMEOS launch gains traction with 37% sequential revenue growth, positive cash flow and expanding patient access as competition looms.


Citizens Raises Papzimeos Sales Forecast After Precigen’s Q3 Topline Beat – Sees 142% Upside Potential In PGEN Stock

Equity

Citizens raised its Q4 sales forecast for Papzimeos to $88 million from $65 million.


Precigen, Inc. (PGEN) Q3 Earnings and Revenues Miss Estimates

Precigen (PGEN) delivered earnings and revenue surprises of -11.11% and -1.70%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance

Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of GuidancePR...

Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?

PGEN's Q3 results hinge on Papzimeos sales momentum and pipeline updates as competitive threat grows from a newly approved RRP therapy.

PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings 

Stocktwits sentiment for PGEN hit a record 94/100 in ‘extremely bullish’ territory, with Wednesday’s earnings approaching.

PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval

The FDA granted accelerated approval to Inovio Pharmaceuticals’ (INO) Voceryq, a plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis.


C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

C4 Therapeutics (CCCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4

Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4 Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4PR NewswireGERMANTOWN, Md., Oct. 28, 2026 GERMANTOWN, Md., Oct. 28, 2026 /PRNewswire/ -- Precigen...

• Reported GAAP EPS of $0.08 up 107.55% YoY
• Reported revenue of $74.15M up 2439.38% YoY
• Precigen expects Papzimeos product costs, excluding significant period costs, to increase as a percentage of product revenue in future periods compared with periods using pre-launch inventory.

Precigens Papzimeos product costs are expected to increase as a percentage of revenue after pre-launch inventory sales; all Papzimeos product revenue flows through one wholesaler, and debt carries floating interest.

Precigen recorded $72.9M in Q3 Papzimeos product revenue; Papzimeos has full FDA approval without a confirmatory trial, and AdenoVerse received FDA platform technology designation.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Precigen reported Q3 revenue of $74.1 million, above Wall Street estimates of $71.6 million, according to Fiscal.ai.</li><li>Precigen achieved its first-ever cash-flow-positive quarter ahead of guidance.</li><li>The company posted net income of $35.8 million, compared with a net loss a year earlier.</li></ul>Precigen (PGEN) was on investors’ radar on Thursday, after the biotech firm reported a better-than-expected third-quarter print led by sales of its recurrent respiratory papillomatosis (RRP) drug, prompting Citizens to raise its price target on the stock.Citizens raised PGEN’s price target to $12 from $11 and maintained a ‘Market Outperform’ rating, according to Investing.com. The new target implies about 142% upside from current levels.Despite the earnings beat and the bullish analyst update, <a class="mention" data-mention="$PGEN" data-symbol-id="PGEN" href="https://stocktwits.com/symbol/PGEN" target="_blank">PGEN shares</a> slid 2% in pre-market trading.<h2 class="st-heading-2">Citizens Sees Stronger Papzimeos Sales</h2>Precigen reported Q3 revenue of $74.1 million, up from $2.9 million a year earlier, and above Wall Street estimates of $71.6 million, according to Fiscal.ai. Citizens said Papzimeos generated $72.9 million in sales, beating its $60 million forecast.The company posted net income of $35.8 million, or $0.08 per share, compared with a net loss a year earlier. Crucially, Precigen generated $11.9 million in operating cash flow, achieving its first-ever cash-flow-positive quarter ahead of guidance. It held $51 million in cash, cash equivalents and investments as of Sept. 30.<h2 class="st-heading-2">Citizens Raises Papzimeos Sales Guidance</h2>Citizens raised its Q4 sales forecast for the drug to $88 million from $65 million and increased its full-year 2027 estimate to $429 million from $303 million.Papzimeos received FDA approval in August 2025 to treat adults with RRP, a rare HPV-related disease that causes recurring growths in the airways, potentially affecting breathing and speech.Precigen is currently conducting a redosing study of Papzimeos while also seeking European approval for the drug. Its experimental cancer therapy PRGN-2009 is undergoing Phase 2 trials for HPV-related throat and cervical cancers. Citizens expects updated Phase 2 cancer data in Q4 of 2026.<h2 class="st-heading-2">Retail Says PGEN Is Undervalued</h2>Despite the pre-market slide, retail sentiment on PGEN on Stocktwits remained ‘extremely bullish’ over the past 24 hours, while message volumes rose 225%.<img src="https://news.stocktwits-cdn.com/PGEN_7f70910da8.png" alt="PGEN.png">One user called the stock ‘undervalued,’ adding that it should be worth at least $8.<stembedurl>https://stocktwits.com/MinoXZ/message/668231657</stembedurl>PGEN shares have gained more than 18% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Precigen's logo is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Citizens raised its Q4 sales forecast for Papzimeos to $88 million from $65 million.

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$0.11	--	--	N/A
Q3 '26	$0.06	$0.08	33.33%	BEAT
Q2 '26	-$0.01	$0.05	514.25%	BEAT
Q1 '26	-$0.03	-$0.02	40.48%	BEAT
Q4 '25	-$0.08	--	--	N/A

Feed

News

Sentiment

Earnings

Fundamentals

Info

PGEN Earnings

Latest Earnings Results: Q3 '26

Historical Earnings